跳至主要内容
临床试验/IRCT2016031320441N3
IRCT2016031320441N3已完成未知

Role of Omega-3 in the prevention of contrast-induced nephropathy

Vice chancellor for research, Shiraz University of Medical Sciences, International branch0 个研究点目标入组 80 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 80 years(—)
性别
All

入选标准

  • Inclusion criteria included chronic kidney disease with GFR 15- 60 ml/min/1.73 m2, the ages of 18 to 80 years, and patients undergoing elective PCI. Exclusion criteria: Pretreatment with N-acetyl cystein or intravenous vitamin C; sensitivity or tolerance to ASA or Clopidogrel or omega-3; sever adverse effects to drugs

排除标准

  • 未提供

研究者

发起方
Vice chancellor for research, Shiraz University of Medical Sciences, International branch

相似试验